Clinical trial

A Study of Abatacept in Patients With Active Crohn's Disease

NCT00406653 · Bristol-Myers Squibb, Industry · Terminated

Key facts

NCT number NCT00406653
Title A Study of Abatacept in Patients With Active Crohn's Disease
Official title A Phase 3, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy With Abatacept in Subjects With Active Crohn's Disease (CD) Who Have Had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
Lead sponsor Bristol-Myers Squibb, Industry
Status Terminated
Phase Phase 3
Study type Interventional
Conditions Crohn's Disease
Intervention type Drug
Interventions abatacept, placebo
Enrollment 451
Start date Dec 1, 2006
Primary completion Nov 1, 2009
Completion Nov 1, 2009
First posted Dec 4, 2006
Last update posted Sep 14, 2010
Countries Australia, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, India, Italy, Mexico, Netherlands and 5 more

At a glance

  • 100–999 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies